ZBHZimmer Biomet Holdings, Inc.

Ticker: ZBH | Price: $109.59 | Today's Change: +12.94% Filing: Form 8-K (Items 2.02, 9.01) | Filed with the SEC: November 4, 2026

---

What Happened

Zimmer Biomet Holdings, Inc. filed an 8-K with the SEC on November 4, 2026, disclosing its Q2 FY2026 financial results under Item 2.02 (Results of Operations and Financial Condition). The company reported revenue of $3.986 billion, net income of $334.9 million, and operating income of $592.3 million for the quarter. Diluted earnings per share came in at $1.68, with basic EPS at $1.69.

---

Why It Matters

The scale of today's market reaction — shares up nearly 13% — signals that these results came in well ahead of market expectations, though the structured filing data alone does not include comparative consensus figures. For investors, the key practical takeaways are:

• Revenue approaching $4 billion in a single quarter underscores the breadth and scale of Zimmer Biomet's orthopedic implant and surgical technology business.
• Operating income of $592.3 million implies a healthy operating margin on that revenue base, pointing to disciplined cost management alongside top-line growth.
• Net income of $334.9 million and diluted EPS of $1.68 represent tangible bottom-line delivery, not just revenue growth.
• The magnitude of the share price move suggests investors may have been positioned cautiously heading into this print, making the upside surprise particularly impactful.

This filing follows StockWatch's existing initiating coverage on ZBH, published September 8, 2026, which had already flagged the company as one to watch.

---

Analysis

A ~13% single-day surge in a large-cap medtech name is a meaningful signal. Zimmer Biomet operates in the orthopedic reconstruction space — hips, knees, spine, and related surgical products — which has historically benefited from aging demographics and recovering procedure volumes post-pandemic. A quarter delivering nearly $4 billion in revenue with over half a billion in operating income suggests those secular tailwinds are translating effectively into financial performance.

The key questions to watch going forward include:

• Guidance revision: Did management update its full-year FY2026 outlook alongside these results? The 8-K filing itself (Items 2.02 and 9.01) typically contains a press release with guidance language — investors will want to scrutinize any raised or maintained targets.
• Geographic and segment mix: At this revenue scale, the split between U.S. and international markets, as well as between large joints (hips/knees) and other segments, will be critical to understanding the durability of this performance.
• Margin trajectory: Operating income of $592.3 million on revenue of $3.986 billion implies roughly a 14.9% operating margin. Whether this is expanding, stable, or under pressure from cost inflation or pricing dynamics is a key follow-on data point.
• Share price vs. prior coverage: With ZBH now trading at $109.59 — above the price target cited in StockWatch's September 2026 initiation — the stock's re-rating will be a topic for updated coverage to address.

The filing date of November 4, 2026, means this disclosure may have landed after a prior trading session's close, with today's move reflecting the first full market reaction. The strength of that reaction reinforces the materiality of these results.

---

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, an offer to buy or sell securities, or an equity research recommendation of any kind. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions. Financial data cited is sourced exclusively from the company's official XBRL filing data as submitted to the SEC.

Existing Coverage

StockWatch has full coverage on ZBH, published 2026-09-08. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-04. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1136869/000119312526446145/zbh-20261104.htm